Pharma Pioneer

Faron's Webcast on BEXMAB Phase 1 Data and Bexmarilimab Updates

19 May 2024
2 min read

Faron Pharmaceuticals, a biopharmaceutical firm specializing in innovative immunotherapies, has announced the scheduling of a virtual BEXMAB study update session. The event, which will not require any special software or plugins to join, is set to take place on March 19, 2024, at 11:00 EET/9:00 am GMT. The meeting will feature discussions on the latest findings from the BEXMAB clinical trial involving patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), focusing on the long-term effectiveness of bexmarilimab when combined with standard care treatments.

Key speakers at the event will include Dr. Mika Kontro, an Associate Professor at the University of Helsinki and the principal investigator of the BEXMAB study, Dr. Maija Hollmen, the Chief Scientific Officer at Faron, Dr. Juho Jalkanen, the Chief Operating Officer at Faron, and other members of the company's senior leadership. The session will provide insights into myeloid leukemia, the unique mechanism of action of bexmarilimab, and the company's insights into the drug's efficacy in both the short and long term. Faron will also discuss the future development plans for bexmarilimab and its business prospects. The event will be interactive, with a Q&A segment, and parts of the discussion will be conducted in Finnish, followed by a summary in English.

Bexmarilimab, Faron's proprietary immunotherapy, is currently under investigation in a Phase 1/2 clinical trial. The drug is designed to target Clever-1, a receptor that is highly expressed in AML and MDS cells and is associated with poor treatment outcomes. By binding to Clever-1, bexmarilimab aims to reprogram myeloid cells, potentially enhancing the body's immune response against cancer cells and improving the effectiveness of standard treatments.

Faron Pharmaceuticals is a global clinical-stage company dedicated to developing novel therapies for cancer treatment. The company's lead product, bexmarilimab, is a humanized antibody that targets myeloid cell function to counteract cancer's immunosuppressive mechanisms. Faron is exploring the potential of bexmarilimab in combination with standard treatments for hematological cancers.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Gynica Initiates Innovative IntraVag© Clinical Trial for Endometriosis Treatment
Pharma Pioneer
3 min read
Gynica Initiates Innovative IntraVag© Clinical Trial for Endometriosis Treatment
19 May 2024
The clinical trial will explore Gynica's proprietary cannabinoid-based formulations, which are administered intravaginally, leveraging the therapeutic potential of cannabinoids in women's health.
Read →
Positive Phase 1 Results for IMM-1-104 in RAS-Mutant Tumor Clinical Trial
Pharma Pioneer
3 min read
Positive Phase 1 Results for IMM-1-104 in RAS-Mutant Tumor Clinical Trial
19 May 2024
Immuneering Corporation has reported encouraging results from the Phase 1 segment of its Phase 1/2a clinical trial for IMM-1-104.
Read →
RECCE® 327 Phase I/II Trial Advances with Next Dosage Cohort for UTIs and Urosepsis
Pharma Pioneer
2 min read
RECCE® 327 Phase I/II Trial Advances with Next Dosage Cohort for UTIs and Urosepsis
19 May 2024
Recce Pharmaceuticals Ltd, a company focused on developing synthetic anti-infectives to combat antibiotic resistance and emerging viral threats, has initiated a new phase in its clinical trials.
Read →
Promising Early Results from NXP800 Trial in Treating Platinum-Resistant Ovarian Cancer
Pharma Pioneer
2 min read
Promising Early Results from NXP800 Trial in Treating Platinum-Resistant Ovarian Cancer
19 May 2024
Preliminary results from a Phase 1b clinical trial of the drug NXP800, developed by Nuvectis Pharma, Inc., have shown promising signs in the treatment of platinum-resistant ARID1a-mutated ovarian cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.